Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Rein Therapeutics, Inc. Common Stock

RNTX

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Last trade $0.3354
Day change -$0.0646 (-16.15%)
Day range $0.327 – $0.415
Volume 1,833,227
Market cap $35M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$34.51M
Price / earnings
—
Price / book
3.38×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.25×

Profitability

Earnings per share
-$0.58
Return on assets
-75.43%
Return on equity
-487.9%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.27×
Quick ratio
4.27×
Cash ratio
0.88×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.83M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RNTX, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025
Revenue$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0
Selling, general and administrative$2.44M$2.16M$1.96M$3.81M$2.58M$2.56M
Research and development$3.64M$3.07M$2M$1.68M$4.29M$3.05M
Total operating expenses$6.08M$5.23M$32.66M$5.49M$6.87M$5.61M
Operating income-$6.08M-$5.23M-$32.66M-$5.49M-$6.87M-$5.61M
Interest expense$0$0$0$0$0$0
Income before taxes-$6.38M-$5.84M-$32.68M-$5.58M-$6.82M-$5.5M
Income taxes$0$0-$712K$0$0$0
Net income-$6.38M-$5.84M-$31.97M-$5.58M-$6.82M-$5.5M
Net income attributable to common shareholders-$6.38M-$5.84M-$31.97M-$5.58M-$6.82M-$5.5M
EBITDA-$6.08M-$5.23M-$3.96M-$5.49M-$6.87M-$5.61M
Basic earnings per share-$0.10-$0.19-$1.09-$0.21-$0.28-$0.25
Diluted earnings per share-$0.10-$0.19-$1.09-$0.21-$0.28-$0.25

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Rein Therapeutics completed a $57.5 million underwritten public offering of common stock, including full exercise of the over-allotment option. The company will use net proceeds to fully fund its Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis and support operations into Q1 2028. The offering was backed by healthcare-focused investors including Adar1 Capital Management, Ikarian Capital, and Bios Partners.

GlobeNewswire Inc.

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Rein Therapeutics priced a public offering of 50 million shares at $1.00 per share, raising $50 million in gross proceeds. The company plans to use net proceeds to fully fund its Phase 2 clinical trial of LTI-03 for idiopathic pulmonary fibrosis and for working capital. Based on current operating plans, the company believes the proceeds combined with existing cash will fund operations into 2028.

GlobeNewswire Inc.

Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight

The idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designations, positive clinical trial data, and FDA clinical hold lifts for several promising candidates in 2025-2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.